Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

Journal of Virology

Volumn 74, Issue 23, 2000, Pages 10903-10910

  Rose, N F ^a   Roberts, A ^a   Buonocore, L ^a   Rose, J K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS TYPING;

AIDS VACCINES; ANIMALS; FEMALE; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV ANTIBODIES; HIV-1; IMMUNIZATION, SECONDARY; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC; VACCINIA VIRUS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 0034467097     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.23.10903-10910.2000     Document Type: Article

References (42)

1. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
2. Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: Entry by a pH-independent pathway
3. A vaccine for HIV type 1: The antibody perspective
4. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
5. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1
6. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
7. A dual-tropic primary HIV-1 isolate that uses fusin and the beta- chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
8. Binding interactions of glycoproteins with lectins
9. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities
10. Isolation of vesicular stomatitis virus from an infected laboratory worker
11. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
12. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes
13. Nucleotide sequence of a cDNA clone encoding the entire glycoprotein from the New Jersey serotype of vesicular stomatitis virus
14. New observations on cellular immune responses to HIV and T-cell epitopes
15. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: High-level production of virus-like particles containing HIV envelope
16. Epizootiology of vesicular stomatitis
17. Human infection with the virus of vesicular stomatitis
18. +cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins
19. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV)
20. The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody
21. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals
22. Enzyme immunoassays and related procedures in diagnostic medical virology
23. Recombinant vesicular stomatitis viruses from DNA
24. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes
25. Progress in the development of an HIV-1 vaccine
26. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
27. Structure and expression of the glycoprotein gene of Chandipura virus
28. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
29. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
30. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
31. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein
32. Attenuated vesicular stomatitis viruses as vaccine vectors
33. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
34. A new cationic liposome reagent mediating nearly quantitative transfection of animal cells
35. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
36. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies
37. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus
38. Ecological studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity
39. Rhabdoviridae: The viruses and their replication
40. The antigenic structure of the HIV gp120 envelope glycoprotein
41. Cell-mediated immunity to vesicular stomatitis virus infections in mice